This week, Dr. Jack Cush reviews the news with special guest, Dr. Peter Nash. They discuss COVID Autoantibodies, SpA life expectancy, HCQ, extraarticular RA and our approach to Early RA referrals and pre-clinical RA.Read Article
Dr. Jack Cush reviews the news and journal reports from the wonderful wide world of Rheumatology. This week:
Swedish study of 325 #AAV pts saw CVA in 35 pts (8%); CVA incidence=11.3/1000 PYs - this was higher than gen population [SIR 1.85). AAV CVA risk factors included age
Research from the COVID-19 Global Rheumatology Alliance included surveys and data gathering from rheumatology patients. During the pandemic era there was rapid adoption of telemedicine by rheumatologists; and a recent study of patient perspectives shows that most found telemedicine to be atRead Article
In 2018, Park et al showed optimal responses to influenza vaccination in RA patients was best achieved by holding methotrexate for 2 weeks following immunization, with improved humoral responses. Now, a followup trial suggests that equivalent results are had by holding MTX for only 1 week withRead Article
Do abatacept, cenicriviroc, or infliximab improve time to recovery for patients hospitalized with COVID-19 pneumonia compared with standard care?
Findings A randomized, double-masked, placebo-controlled master protocol clinical trial found that treatment with abatacept ABA),Read Article
Dr. Jack Cush reviews the news and reports from the past week on RheumNow.com. This week a new colchicine FDA approval, rising rate of IgG4 related disease and what's the safest biologic?
An RCT of 1136 newly COVID test positive pts compared long term outcomes if immediately
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. This week we delve into some odd associations, repeat drug warnings and the consequences of antirheumatic therapies.
Subanalysis of the tofacitinib ORAL Surveillance study shows the JAK
Opportunistic and chronic infections may be rare and are often difficult to diagnose, especially in patients with autoimmune inflammatory rheumatic diseases (AIIRD), that may be immunocompromised. A EULAR task force has established recommendations for screening and prophylaxis against OI.Read Article